Nocionix,Inc. — SEC Form D Filing

Nocionix,Inc. filed an SEC Form D on November 4, 2026, reporting $2.70M raised in Other Health Care.

Form D filing details

Filing
SEC Form D
Filing date
November 4, 2026
Amount reported
$2.70M
Round stage
Seed funding stage based on the $2.7 million raised through convertible notes for early clinical development.
Industry
Other Health Care
Website
https://www.nocionix.com

What the company does

Securities: Debt, Convertible notes and equity issuable upon any conversion thereof. Exemption: Rule 506(b). Incorporated: DELAWARE

Problem

Chronic pain and neurological conditions lack targeted, non-addictive therapies that safely attenuate pain signals without systemic side effects.

Solution

Nocionix develops novel therapeutics targeting peripheral nociceptive pathways to treat severe pain conditions.

Why now

Regulatory mandates prioritizing non-opioid pain treatments combined with advances in targeted nociceptor pharmacology enable safer pain management solutions.

Source: SEC EDGAR Form D filing